8-K: Traws Pharma Doses First Subject in Phase 2 COVID Study

Traws Pharma initiates Phase 2 trials for ratutrelvir, a ritonavir-free COVID treatment, with results expected by year-end 2025.

Summary

• Traws Pharma, Inc. announced the dosing of the first subject in its Phase 2 study for ratutrelvir, a ritonavir-free anti-viral treatment for newly diagnosed COVID subjects.
• The primary trial will compare ratutrelvir against PAXLOVID, evaluating safety, infection rates, COVID symptoms, disease rebound, and incidence of Long COVID.
• A separate single-arm trial will assess ratutrelvir's safety and efficacy in PAXLOVID-ineligible patients, a vulnerable population with limited treatment options.
• Top-line data from both Phase 2 studies are anticipated by year-end 2025.
• Ratutrelvir is an investigational oral, small molecule Mpro (3CL protease) inhibitor designed to be broadly active against SARS-CoV-2/COVID-19 without requiring ritonavir.
• Preclinical and Phase 1 studies indicate ratutrelvir avoids ritonavir-associated drug-drug interactions and allows for once-daily, single tablet dosing for 10 days.
• Phase 1 data showed ratutrelvir maintained target blood plasma levels approximately 13 times above the EC50 with the target Phase 2 dosing regimen (600 mg/day for ten days), potentially reducing clinical rebound and Long COVID risk.
• The COVID treatment market represents a potential multi-billion dollar opportunity.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the advancement of a key drug candidate into Phase 2 trials, addressing a significant market need with a potentially differentiated product (ritonavir-free). The expectation of results by year-end 2025 provides a clear near-term catalyst. However, it's still an early-stage trial, and success is not guaranteed, hence not a perfect 10.

Positives

• Initiation of Phase 2 trials for ratutrelvir, a significant step in its development as a potential COVID-19 treatment.
• Ratutrelvir is a ritonavir-free treatment, which could avoid drug-drug interactions associated with ritonavir and enable wider patient use.
• The drug's good overall tolerability allows for convenient once-daily, single tablet dosing for 10 days.
• Potential to reduce rates of disease rebound and the risk of Long COVID, addressing key shortcomings of current treatments.
• Targeting PAXLOVID-ineligible patients addresses a significant, vulnerable population with few existing treatment options.
• The COVID treatment market is identified as a potential multi-billion dollar opportunity, indicating substantial commercial potential.
• Positive results from these trials could provide important proof-of-concept data and represent a valuable inflection point for the program.

Risks

• Substantial risks and uncertainties are involved in forward-looking statements, and actual results may differ from expectations.
• The success and timing of Traws' clinical trials, including when results of the Phase 2 studies of ratutrelvir will be reported, are uncertain.
• There is no guarantee regarding the potential efficacy of ratutrelvir for the treatment of COVID-19.
• Uncertainty exists regarding ratutrelvir's ability to gain market acceptance, if and when regulatory approval is obtained, or to become the new standard of care.
• Risks associated with Traws' interactions with regulatory bodies like the FDA, BARDA, and similar foreign regulators.
• Market conditions, regulatory requirements, and pathways for approval can impact the program.
• The ongoing need for improved therapy to reduce the frequency of clinical rebound and the concomitant risk for Long COVID may not be fully met by ratutrelvir.
• The extent of the spread and threat of bird flu, another area of Traws' focus, presents ongoing risks.
• Traws' ability to raise additional capital when needed is a risk factor.

Future Outlook

Traws Pharma expects to report top-line data from both Phase 2 studies for ratutrelvir by year-end 2025. Management believes ratutrelvir has the potential to overcome shortcomings of current treatments and become the new standard of care, particularly given its ritonavir-free nature and potential to reduce disease rebound and Long COVID risk.

Management Comments

• "The first trial will enable Traws to compare ratutrelvir, a potential best in class ritonavir-free agent, against the current gold standard, PAXLOVID." Iain D. Dukes, MA, DPhil, Chief Executive Officer of Traws Pharma.
• "This study will evaluate safety, as well as rates of infection, COVID symptoms, disease rebound and incidence of Long COVID." Iain D. Dukes, MA, DPhil, Chief Executive Officer of Traws Pharma.
• "We will initiate a second trial to evaluate the safety and efficacy of ratutrelvir in PAXLOVID-ineligible patients, a population at risk for poor outcomes from COVID infection with few available treatment options." Iain D. Dukes, MA, DPhil, Chief Executive Officer of Traws Pharma.
• "Our expectation is to be able to report the results of both Phase 2 studies by year-end 2025." Iain D. Dukes, MA, DPhil, Chief Executive Officer of Traws Pharma.
• "Across the US, we see multiple signs that COVID continues to threaten public health, especially among elderly and vulnerable individuals." Robert R. Redfield, MD, Chief Medical Officer of Traws Pharma.
• "We believe that Traws ritonavir-free COVID therapeutic candidate, ratutrelvir, has the potential to overcome the shortcomings of current treatments and become the new standard of care." Robert R. Redfield, MD, Chief Medical Officer of Traws Pharma.
• "Ratutrelvir's good overall tolerability allows once-daily, single tablet dosing for 10 days, which could reduce the rate of rebound and the risk of Long COVID." Robert R. Redfield, MD, Chief Medical Officer of Traws Pharma.
• "Positive results could provide important proof-of-concept data and represent a valuable inflection point for the program." Robert R. Redfield, MD, Chief Medical Officer of Traws Pharma.

Industry Context

The announcement positions Traws Pharma's ratutrelvir as a potential competitor to existing COVID-19 treatments, specifically PAXLOVID, by offering a ritonavir-free alternative. This addresses a significant unmet need for patients who cannot take ritonavir due to drug-drug interactions, and for the broader population seeking treatments that may reduce disease rebound and Long COVID. The continued threat of COVID-19, especially among vulnerable populations, underscores the ongoing demand for effective and well-tolerated antiviral therapies, indicating a sustained multi-billion dollar market opportunity.

Comparison to Industry Standards

• Ratutrelvir is being evaluated against PAXLOVID, currently considered the 'gold standard' for COVID-19 treatment, in a non-inferiority trial.
• A key differentiator for ratutrelvir is its ritonavir-free formulation, which aims to overcome the drug-drug interaction limitations associated with ritonavir-boosted treatments like PAXLOVID.
• The trial design includes assessing rates of disease rebound and incidence of Long COVID, areas where current treatments, including PAXLOVID, have shown limitations or ongoing concerns.
• Traws Pharma is also specifically targeting PAXLOVID-ineligible subjects, a population with few available treatment options, indicating an attempt to fill a critical gap in the market.
• The company cites Pfizer Inc.'s 2024 10K report (Feb 27, 2025) as a source for the multi-billion dollar market opportunity in COVID treatment, suggesting a competitive landscape with established players.

Stakeholder Impact

• **Shareholders:** Potential for increased shareholder value if clinical trials are successful, leading to market approval and commercialization of ratutrelvir.
• **Patients:** Offers a potential new, ritonavir-free treatment option for COVID-19, especially for those ineligible for current therapies or seeking reduced risk of rebound/Long COVID.
• **Healthcare Providers:** Provides a new tool in the fight against COVID-19, potentially simplifying treatment regimens due to once-daily dosing and fewer drug-drug interactions.
• **Employees:** Continued employment and potential growth opportunities within the company as drug development progresses.
• **Regulatory Authorities:** Will be closely monitoring trial progress and results for potential approval pathways.

Next Steps

• Continue the Phase 2 study comparing ratutrelvir against PAXLOVID in newly diagnosed COVID subjects.
• Initiate a separate single-arm Phase 2 trial to evaluate ratutrelvir in PAXLOVID-ineligible subjects.
• Report top-line data from both Phase 2 studies by year-end 2025.
• Actively seek development and commercialization partners for legacy clinical oncology programs (rigosertib and narazaciclib).

Key Dates

Recommendation

The announcement of a Phase 2 trial initiation is a positive development for a clinical-stage biopharmaceutical company, indicating progress in its pipeline. However, it is not a definitive outcome. Investors should 'hold' as the stock's future performance will largely depend on the successful completion of these trials and the top-line data expected by year-end 2025. While the ritonavir-free aspect and target population are compelling, the inherent risks of clinical development warrant a cautious approach until more concrete results are available.

Keywords

Traws Pharma, ratutrelvir, COVID-19, Phase 2 clinical trial, ritonavir-free, antiviral, biopharmaceutical, PAXLOVID, Long COVID, Mpro inhibitor